The purpose of this study is to measure safety, tolerability and PK of a single dose of AZD5148 administered via IV bolus or IM injection in healthy Japanese participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Japanese participants with adverse events (AEs).
Timeframe: From Randomization (Day -1 or Day 1) to Day 91
Number of participants with serious adverse events (SAEs)
Timeframe: From Screening (Day -28 to Day -2) to final Follow-up Visit (Day 361)
Number of participants with adverse events of special interest (AESIs)
Timeframe: From Randomization (Day -1 or Day 1) to final Follow-up Visit (Day 361)